A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase

Protein Science

Volumn 7, Issue 11, 1998, Pages 2249-2255

  Fox, Ted ^a   Coll, Joyce T ^a   Xie, Xiaoling ^a   Ford, Pamella J ^a   Germann, Ursula A ^a   Porter, Margaret D ^a   Pazhanisamy, S ^a   Fleming, Mark A ^a   Galullo, Vincent ^a   Su, Michael S S ^a   Wilson, Keith P ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Asthma; ATP binding site; Cancer; ERK2; Iodotubercidin; MAP kinase; p38; Pyridinyl imidazole

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 IODOTUBERCIDIN; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; SYNAPTOPHYSIN;

AMINO ACID SUBSTITUTION; ARTICLE; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; INFLAMMATION; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

EID: 0031793432     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560071102     Document Type: Article

References (35)

1. Anderson NG, Maller JL, Tonks NK, Sturgill TW. 1990. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343:651-653.
2. Bjorbaek C, Zhao Y, Moller DE. 1995. Divergent functional roles for p90rsk kinase domains. J Biol Chem 270:18848-18852.
3. Bokemeyer D, Sorokin A, Dunn MJ. 1996. Multiple intracellular MAP kinase signaling cascades [Editorial]. Kidney Int 49:1187-1198.
4. Brünger AT. 1992. XPLOR: A system for X-ray crystallography and NMR, Version 3.1. New Haven, Connecticut: Yale University Press.
5. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. 1997. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90:859-869.
6. Chen RH, Abate C, Blenis J. 1993. Phosphorylation of the c-fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci USA 90:10952-10956.
7. Cobb MH, Goldsmith EJ. 1995. How MAP kinases are regulated. J Biol Chem 270:14843-14846.
8. Cottam HB, Wasson DB, Shih HC, Raychaudhuri A, Di Pasquale G, Carson DA. 1993. New adenosine kinase inhibitors with oral antiinflammatory activity: Synthesis and biological evaluation. J Med Chem 36:3424-3430.
9. Crews CM, Alessandrini A, Erikson RL. 1992. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258:478-480.
10. Cuenda A, Cohen P, Buee SV, Goedert M. 1997. Activation of stress-activated protein kinase-3 (SAPK3) by cytokines and cellular stresses is mediated via SAPKK3 (MKK6); comparison of the specificities of SAPK3 and SAPK2 (RK/p38). EMBO J 16:295-305.
11. Cuenda A, Rouse J, Doza YN, Meier R. Cohen P, Gallagher TF, Young PR, Lee JC. 1995. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364:229-233.
12. Davis RJ. 1995. Transcriptional regulation by MAP kinases. Mol Reprod Dev 42:459-467.
13. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. 1994. JNK1 : A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-jun activation domain. Cell 76:1025-1037.
14. Frey RS, Mulder KM. 1997. Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor beta in the negative growth control of breast cancer cells. Cancer Res 57:628-633.
15. Gonzalez FA, Raden DL, Davis RJ. 1991. Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases. J Biol Chem 266:22159-22163.
16. Han J, Lee JD, Bibbs L, Ulevitch RJ. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265:808-811.
17. Huang W, Erikson RL. 1994. Constitutive activation of Mek1 by mutation of serine phosphorylation sites. Proc Natl Acad Sci USA 91:8960-8963.
18. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746.
19. Massillon D, Stalmans W, van de Werve G, Bollen M. 1994. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem J 299:123-128.
20. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. 1993. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase [see comments]. Science 260:1658-1661.
21. Morrison JF, Walsh CT. 1988. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201-301.
22. Newby AC, Holmquist CA, Illingworth J, Pearson JD. 1983. The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem J 214:317-323.
23. Oliver BL, Sha'afi RI, Hajjar JJ. 1995. Transforming growth factor-alpha and epidermal growth factor activate mitogen-activated protein kinase and its substrates in intestinal epithelial cells. Proc Soc Exp Biol Med 210:162-170.
24. Otwinowski Z, Minor W. 1996. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
25. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ. 1995. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270:7420-7426.
26. Raingeaud J, Whitmarsh AJ, Barrett T, Derijard B, Davis RJ. 1996. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 16:1247-1255.
27. Rouse J, Cohen P, Trigon S, Morange M, Alonso LA, Zamanillo D, Hunt T, Nebreda RA. 1994. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78:1027-1037.
28. Shapiro L, Dinarello CA. 1995. Osmotic regulation of cytokine synthesis in vitro. Proc Natl Acad Sci USA 92:12230-12234.
29. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC 1997. Hyperexpression of mitogen-activated protein kinase in human breast cancer [see comments]. J Clin Invest 99:1478-1483.
30. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, Brown ML, Pargellis CA. 1997. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 4:311-316.
31. Wang Z, Harkins PC, Ulevitch RJ, Han J, Cobb MH, Goldsmith EJ. 1997. The structure of mitogen-activated protein kinase p38 at 2.1 Åresolution. Proc Natl Acad Sci USA 94:2327-2332.
32. Whelchel A, Evans J, Posada J. 1997. Inhibition of ERK activation attenuates endothelin-stimulated airway smooth muscle cell proliferation. Am J Respir Cell Mol Biol 16:589-596.
33. Wilson KP, Fitzgibbon MJ, Caron PR, Griffith JP, Chen W, McCaffrey PG, Chambers SP, Su MS. 1996. Crystal structure of p38 mitogen-activated protein kinase. J Biol Chem 271:27696-27700.
34. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW, Fitzgibbon MJ, Caron PR, Murcko MA, Su MSS. 1997. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 4:223-231.
35. Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ. 1994. Atomic structure of the MAP kinase ERK2 at 2.3 Åresolution [see comments]. Nature 367:704-711.